---
title: "Oncology Institute - CW22 | 8-K: FY2025 Q3 Revenue: USD 136.56 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/265790086.md"
datetime: "2025-11-13T21:16:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265790086.md)
  - [en](https://longbridge.com/en/news/265790086.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265790086.md)
generator: "portal-rs"
---

# Oncology Institute - CW22 | 8-K: FY2025 Q3 Revenue: USD 136.56 M

Revenue: As of FY2025 Q3, the actual value is USD 136.56 M.

EPS: As of FY2025 Q3, the actual value is USD -0.14.

EBIT: As of FY2025 Q3, the actual value is USD -6.134 M.

### Segment Revenue

-   **Consolidated Revenue**: $136.6 million, a 36.7% increase from $99.9 million in Q3 2024.
-   **Fee-for-service Revenue**: Grew by 13% over Q3 2024, driven by organic growth in Florida and Oregon.
-   **Retail Pharmacy and Dispensary Revenue**: Contributed $75.9 million in revenue and $12.8 million in gross profit in Q3 2025.

### Operational Metrics

-   **Gross Profit**: $18.9 million, an increase of 31.7% from the previous year.
-   **Net Loss**: $16.5 million compared to a net loss of $16.1 million in Q3 2024.
-   **Adjusted EBITDA**: Improved to - $3.5 million from - $8.2 million in Q3 2024.

### Cash Flow

-   **Cash and Cash Equivalents**: $27.7 million as of September 30, 2025.
-   **Free Cash Flow**: - $26.9 million for the nine months ended September 30, 2025, compared to - $29.4 million in the same period of 2024.

### Unique Metrics

-   **Markets**: Expanded to 22 markets from 14 in the previous year.
-   **Lives under Value-based Contracts**: 1.9 million, unchanged from the previous year.

### Outlook / Guidance

-   The Oncology Institute updated its full-year 2025 revenue guidance to $495 to $505 million, up from the previous $460 to $480 million.
-   Adjusted EBITDA guidance was revised to - $11 to - $13 million from the previous - $8 to - $17 million.
-   The company expects Adjusted EBITDA of approximately $0 to $2 million in Q4 2025, assuming a stable global market environment.

### Related Stocks

- [TOIIW.US](https://longbridge.com/en/quote/TOIIW.US.md)
- [STLNW.US](https://longbridge.com/en/quote/STLNW.US.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**